A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Accent Therapeutics
A2 Biotherapeutics Inc.
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
University of Colorado, Denver
GlaxoSmithKline
University of Nebraska
Novartis
Institut du Cancer de Montpellier - Val d'Aurelle
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Sahlgrenska University Hospital
Elicio Therapeutics
Institut Bergonié
Guardant Health, Inc.
ModeX Therapeutics, An OPKO Health Company
Tempus AI
Stanford University
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Universitat Jaume I
Stanford University
Revolution Medicines, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
DxTerity Diagnostics
UTC Therapeutics Inc.
Jules Bordet Institute
University of Aarhus
Assiut University
Dublin City University
Institut de cancérologie Strasbourg Europe
Charite University, Berlin, Germany
Corvus Pharmaceuticals, Inc.
Charite University, Berlin, Germany
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Klus Pharma Inc.
St Vincent's University Hospital, Ireland
Glasgow Royal Infirmary
University of Southampton
Institut de Cancérologie de Lorraine
Weprom
MacroGenics
Oslo University Hospital
Stryker Orthopaedics
SpeciCare
Imperial College London
Abramson Cancer Center at Penn Medicine
City of Hope Medical Center